Hansa Biopharma AB (publ) (HNSA.ST)
SEK 33.3
(17.42%)
SEK 33.3
(17.42%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.01 Billion SEK | -39.67% |
| 2022 | 1.68 Billion SEK | 66.61% |
| 2021 | 1.01 Billion SEK | -29.4% |
| 2020 | 1.43 Billion SEK | 115.96% |
| 2019 | 664.23 Million SEK | -29.7% |
| 2018 | 944.82 Million SEK | 38.86% |
| 2017 | 680.41 Million SEK | 119.01% |
| 2016 | 310.67 Million SEK | 38.64% |
| 2015 | 224.08 Million SEK | 312.6% |
| 2014 | 54.31 Million SEK | 6.96% |
| 2013 | 50.77 Million SEK | -22.83% |
| 2012 | 65.79 Million SEK | 60.89% |
| 2011 | 40.89 Million SEK | 8.19% |
| 2010 | 37.8 Million SEK | -0.91% |
| 2009 | 38.14 Million SEK | -14.98% |
| 2008 | 44.86 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 830.55 Million SEK | -18.42% |
| 2024 Q2 | 1.02 Billion SEK | 23.94% |
| 2024 Q3 | 940.67 Million SEK | -8.62% |
| 2023 FY | 1.01 Billion SEK | -39.67% |
| 2023 Q4 | 1.01 Billion SEK | -13.07% |
| 2023 Q2 | 1.36 Billion SEK | -9.15% |
| 2023 Q1 | 1.49 Billion SEK | -11.12% |
| 2023 Q3 | 1.17 Billion SEK | -14.05% |
| 2022 FY | 1.68 Billion SEK | 66.61% |
| 2022 Q3 | 1.38 Billion SEK | 75.94% |
| 2022 Q1 | 889.49 Million SEK | -12.17% |
| 2022 Q2 | 784.92 Million SEK | -11.76% |
| 2022 Q4 | 1.68 Billion SEK | 22.19% |
| 2021 Q1 | 1.31 Billion SEK | -8.63% |
| 2021 FY | 1.01 Billion SEK | -29.4% |
| 2021 Q3 | 1.09 Billion SEK | -10.34% |
| 2021 Q4 | 1.01 Billion SEK | -7.27% |
| 2021 Q2 | 1.21 Billion SEK | -7.05% |
| 2020 Q4 | 1.43 Billion SEK | -6.02% |
| 2020 Q3 | 1.52 Billion SEK | 232.0% |
| 2020 FY | 1.43 Billion SEK | 115.96% |
| 2020 Q1 | 539.48 Million SEK | -18.78% |
| 2020 Q2 | 459.77 Million SEK | -14.78% |
| 2019 Q2 | 817.8 Million SEK | -8.93% |
| 2019 Q4 | 664.23 Million SEK | -9.67% |
| 2019 Q3 | 735.35 Million SEK | -10.08% |
| 2019 Q1 | 898.03 Million SEK | -4.95% |
| 2019 FY | 664.23 Million SEK | -29.7% |
| 2018 Q1 | 647.43 Million SEK | -4.85% |
| 2018 Q2 | 603.89 Million SEK | -6.73% |
| 2018 Q4 | 944.82 Million SEK | 65.76% |
| 2018 Q3 | 569.98 Million SEK | -5.61% |
| 2018 FY | 944.82 Million SEK | 38.86% |
| 2017 Q4 | 680.41 Million SEK | 249.08% |
| 2017 Q1 | 266.15 Million SEK | -14.33% |
| 2017 Q3 | 194.91 Million SEK | -14.82% |
| 2017 Q2 | 228.82 Million SEK | -14.03% |
| 2017 FY | 680.41 Million SEK | 119.01% |
| 2016 Q3 | 158.77 Million SEK | -12.39% |
| 2016 Q4 | 310.67 Million SEK | 95.67% |
| 2016 Q2 | 181.22 Million SEK | -11.17% |
| 2016 FY | 310.67 Million SEK | 38.64% |
| 2016 Q1 | 204 Million SEK | -8.96% |
| 2015 Q4 | 224.08 Million SEK | -6.6% |
| 2015 Q3 | 239.92 Million SEK | -6.53% |
| 2015 Q2 | 256.67 Million SEK | 370.49% |
| 2015 Q1 | 54.55 Million SEK | 0.45% |
| 2015 FY | 224.08 Million SEK | 312.6% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | 75.61 Million SEK | 0.0% |
| 2014 Q4 | 54.31 Million SEK | 0.0% |
| 2014 FY | 54.31 Million SEK | 6.96% |
| 2013 Q1 | 57.51 Million SEK | -12.59% |
| 2013 FY | 50.77 Million SEK | -22.83% |
| 2013 Q4 | 50.77 Million SEK | 0.32% |
| 2013 Q3 | 50.61 Million SEK | -12.0% |
| 2013 Q2 | 57.51 Million SEK | 0.0% |
| 2012 Q2 | 70.35 Million SEK | 0.0% |
| 2012 FY | 65.79 Million SEK | 60.89% |
| 2012 Q4 | 65.79 Million SEK | 0.0% |
| 2011 FY | 40.89 Million SEK | 8.19% |
| 2011 Q4 | 40.89 Million SEK | 0.0% |
| 2011 Q2 | 53.25 Million SEK | 0.0% |
| 2010 Q2 | 46.73 Million SEK | 0.0% |
| 2010 FY | 37.8 Million SEK | -0.91% |
| 2010 Q4 | 37.8 Million SEK | 0.0% |
| 2009 Q2 | 39.21 Million SEK | 0.0% |
| 2009 Q4 | 38.14 Million SEK | 0.0% |
| 2009 FY | 38.14 Million SEK | -14.98% |
| 2008 Q4 | 44.86 Million SEK | 0.0% |
| 2008 FY | 44.86 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -759.469% |
| Ziccum AB (publ) | 14.97 Million SEK | -6699.633% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -4979.791% |
| BioArctic AB (publ) | 1.18 Billion SEK | 14.167% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -1532.078% |
| Mendus AB (publ) | 755.95 Million SEK | -34.67% |
| Genovis AB (publ.) | 288.85 Million SEK | -252.438% |
| Intervacc AB (publ) | 259.61 Million SEK | -292.141% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -2326.276% |
| Active Biotech AB (publ) | 44 Million SEK | -2213.73% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -265.223% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -1537.986% |
| Aptahem AB (publ) | 63.02 Million SEK | -1515.299% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -105.148% |
| Kancera AB (publ) | 65.64 Million SEK | -1450.875% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -189.764% |
| Fluicell AB (publ) | 9.34 Million SEK | -10799.797% |
| Saniona AB (publ) | 64.14 Million SEK | -1487.143% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -2929.704% |
| Biovica International AB (publ) | 131.4 Million SEK | -674.718% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -1821.376% |
| AcouSort AB (publ) | 34.51 Million SEK | -2849.732% |
| Xintela AB (publ) | 18.39 Million SEK | -5434.335% |
| Abliva AB (publ) | 87.49 Million SEK | -1063.489% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | -33.918% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 19.1% |
| OncoZenge AB (publ) | 20.34 Million SEK | -4905.118% |
| Amniotics AB (publ) | 26.08 Million SEK | -3802.634% |
| 2cureX AB (publ) | 16.62 Million SEK | -6023.555% |
| CombiGene AB (publ) | 120.61 Million SEK | -744.063% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -16652.361% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 46.434% |
| Camurus AB (publ) | 1.9 Billion SEK | 46.639% |
| Corline Biomedical AB | 100.1 Million SEK | -916.973% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -474.771% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -624.084% |
| I-Tech AB | 152.44 Million SEK | -567.817% |
| Cyxone AB (publ) | 43.65 Million SEK | -2232.015% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -1193.703% |
| Biosergen AB | 7.2 Million SEK | -14037.495% |
| Cantargia AB (publ) | 223.71 Million SEK | -355.068% |
| NextCell Pharma AB | 81.28 Million SEK | -1152.388% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | -33.032% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -3274.01% |
| Nanologica AB (publ) | 77.42 Million SEK | -1214.806% |
| SynAct Pharma AB | 228.01 Million SEK | -346.472% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -3703.912% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -4590.811% |
| LIDDS AB (publ) | 17.65 Million SEK | -5666.304% |
| Lipum AB (publ) | 12.11 Million SEK | -8306.614% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 27.292% |
| Alzinova AB (publ) | 123.18 Million SEK | -726.406% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -327.07% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -11940.698% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -1094.505% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -6746.735% |
| Simris Alg AB (publ) | 174.55 Million SEK | -483.231% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -369.061% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -55.781% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -1069.194% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -3471.071% |